AIFM2 and hepatocellular carcinoma: FSP1 inhibitor (iFSP1) exerts a better effect than anti-PD-L1 in prolonging survival time, and the combination of iFSP1 and anti-PD-L1 can further inhibit the progression of HCC in mice 59.